Literature DB >> 14770035

Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction.

Kanneganti G K Murthy1, Chun-Yang Xiao, Jon G Mabley, Min Chen, Csaba Szabó.   

Abstract

Myocardial ischemia-reperfusion can lead to increased oxidative stress both locally and in circulating leukocytes. Oxidant-mediated DNA single strand breaks are known to activate the nuclear enzyme poly(ADP-ribose) polymerase (PARP) in various forms of shock, inflammation, and ischemia-reperfusion injury. The aim of the current study was to investigate whether a local insult such as myocardial ischemia-reperfusion is sufficient to lead to activation of PARP in circulating leukocytes. In anesthetized rats myocardial ischemia-reperfusion was induced by transient ligation of the left anterior descending coronary artery. There was a marked increase in poly(ADP-ribosyl)ation of proteins in homogenates of leukocytes isolated from rats at the end of the reperfusion period. Poly(ADP-ribosyl)ation was inhibited by administration of the pharmacologic PARP inhibitor INO-1001 (30 mg/kg) to the rats. We conclude that local insults, such as myocardial reperfusion injury, are sufficient to activate PARP in circulating leukocytes. PARP activation in circulating cells may mediate certain systemic effects of local ischemia-reperfusion injury such as inflammatory mediator production and remote organ injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14770035     DOI: 10.1097/01.shk.0000110621.42625.10

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

1.  Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.

Authors:  Pál Pacher; Lucas Liaudet; Jon G Mabley; Attila Cziráki; György Haskó; Csaba Szabó
Journal:  Int J Mol Med       Date:  2006-02       Impact factor: 4.101

2.  Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.

Authors:  Emese Tóth-Zsámboki; Eszter Horváth; Katarina Vargova; Eszter Pankotai; Kanneganti Murthy; Zsuzsanna Zsengellér; Tamás Bárány; Tamás Pék; Katalin Fekete; Róbert Gábor Kiss; István Préda; Zsombor Lacza; Domokos Gerö; Csaba Szabó
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

3.  The Angiotensin-converting enzyme inhibitor captopril inhibits poly(adp-ribose) polymerase activation and exerts beneficial effects in an ovine model of burn and smoke injury.

Authors:  Sven Asmussen; Eva Bartha; Gabor Olah; Elena Sbrana; Sebastian W Rehberg; Yusuke Yamamoto; Perenlei Enkhbaatar; Hal K Hawkins; Hiroshi Ito; Robert A Cox; Lillian D Traber; Daniel L Traber; Csaba Szabo
Journal:  Shock       Date:  2011-10       Impact factor: 3.454

4.  Burn and smoke injury activates poly(ADP-ribose)polymerase in circulating leukocytes.

Authors:  Eva Bartha; Sven Asmussen; Gabor Olah; Sebastian W Rehberg; Yusuke Yamamoto; Daniel L Traber; Csaba Szabo
Journal:  Shock       Date:  2011-08       Impact factor: 3.454

Review 5.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 6.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.